Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982682 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01982682 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 41 participants.
The verdict
NCT01982682, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This phase II trial studies how well total-body irradiation, donor lymphocyte infusion, and cyclophosphamide before donor stem cell transplant works in treating patients with high-risk hematologic malignancies. Giving total-body irradiation, donor lymphocyte infusion, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When certain stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Removing the T cells from the donor cells before transplant and giving tacrolimus and mycophenolate mofetil may stop this from happening.
Interventions
- DRUG Cyclophosphamide
- DRUG Mycophenolate mofetil
- RADIATION Total-Body Irradiation (TBI)
- BIOLOGICAL Donor Lymphocyte Infusion (DLI)
- PROCEDURE Allogeneic hematopoietic stem cell transplantation (HSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-11-04 |
| Est. Completion | 2017-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982682
The ClinicalTrials.gov registry entry for NCT01982682 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01982682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982682 about?
NCT01982682 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor". This phase II trial studies how well total-body irradiation, donor lymphocyte infusion, and cyclophosphamide before donor stem cell transplant works in treating patients with high-risk hematologic malignancies. Giving total-body irradiation, donor lymphocyte infusion, and chemotherapy before a donor...
What is the current status of trial NCT01982682?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2013-11-04. Estimated completion is 2017-03-27.
What interventions are being tested in trial NCT01982682?
The interventions under investigation include: Cyclophosphamide (DRUG), Mycophenolate mofetil (DRUG), Total-Body Irradiation (TBI) (RADIATION), Donor Lymphocyte Infusion (DLI) (BIOLOGICAL), Allogeneic hematopoietic stem cell transplantation (HSCT) (PROCEDURE).
Who is sponsoring clinical trial NCT01982682?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.